BioSpace News Archive

Business

Regeneron Reports Third Quarter 2022 Financial and Operating Results

Regeneron Pharmaceuticals, Inc. announced financial results for the third quarter of 2022 and provided a business update.

November 3, 2022
·
25 min read
Genetown

Immuneering Announces Participation in November 2022 Investor Conferences

Immuneering Corporation announced that management will participate in three November investor conferences to share commentary around the Company’s pipeline, platform, and business strategy.

November 3, 2022
·
3 min read
Business

Agios Reports Business Highlights and Third Quarter 2022 Financial Results

Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism pioneering therapies for rare and genetically defined diseases, reported business highlights and financial results for the third quarter ended September 30, 2022.

November 3, 2022
·
11 min read
Business

Kymera Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Business Update

Kymera Therapeutics, Inc. reported business highlights and financial results for the third quarter ended September 30, 2022.

November 3, 2022
·
15 min read
Drug Development

VectivBio Announces Completion of Enrollment for Colon-In-Continuity (CIC) Cohort of STARS Pivotal Phase 3 Study Investigating Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF)

VectivBio Holding AG announced the completion of enrollment of the Colon-in-Continuity cohort for the company’s Phase 3 STARS pivotal study investigating the long-acting synthetic GLP-2 agonist apraglutide in Short Bowel Syndrome with Intestinal Failure.

November 3, 2022
·
4 min read
Business

Xtant Medical Announces Third Quarter 2022 Financial Results

Xtant Medical Holdings, Inc. reported financial and operating results for the third quarter ended September 30, 2022.

November 3, 2022
·
11 min read
Business

Athenex Provides Third Quarter 2022 Financial Results and Business Update

Athenex, Inc. provided a corporate and financial update for the third quarter ended September 30, 2022.

November 3, 2022
·
14 min read
Biotech Bay

Kura Oncology Announces Financing Transactions with Bristol Myers Squibb and Hercules Capital, Providing Access to up to $150 Million

Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, announced a $25 million equity investment from Bristol Myers Squibb and a term loan facility with access to up to $125 million from Hercules Capital, Inc.

November 3, 2022
·
6 min read
Business

IRADIMED CORPORATION Announces Third Quarter 2022 Financial Results

IRADIMED CORPORATION announced its financial results for the three and nine months ended September 30, 2022.

November 3, 2022
·
15 min read
Biotech Beach

Five New Drug Candidates Show Promise as Ainos Pursues Licensing Partners of its Low-dose Oral Interferon Formulation

Ainos, Inc. announced that it is pursuing out-licensing opportunities for five new drug candidates for its low-dose oral interferon-alpha formulation, VELDONA®.

November 3, 2022
·
8 min read